In October 2022, a strategy meeting and advisory board took place in Vienna, in which the key points for the further clinical and regulatory development of VCC-001 were discussed and defined with leading experts from the fields of approval, pharmacology, urology and oncology. Furthermore, approaches for future clinical study planning were discussed, as well as the patient groups that should receive the greatest benefit from treatment with VCC-001.
